Latest news

• BMS’ oral maintenance therapy boosts survival in AML patients

  During a presentation of the results at the annual ASH 2019 conference, Andrew Wei, from the Alfred Hospital and Monash University, Melbourne, Australia, said: “ Based on the results of the QUAZAR ... 11th December 2019.

• J&J and Bristol-Myers Squibb/Bluebird bio reveal rival CAR-T data

  Regeneron also  presented data for its candidate in multiple myeloma at ASH, which demonstrated a 75% response rate in the higher dosed group. ... 10th December 2019.

• Regeneron reveals first data for bispecific antibody in multiple myeloma

  The much anticipated first results from the first two dose groups in the phase 1/2 trial of REGN5458 were presented at ASH 2019. ... 10th December 2019.

• Sangamo steps up BioMarin chase with haemophilia gene therapy data

  Updated results presented at ASH 2019. Sangamo has been playing catch-up with BioMarin in the race to develop a gene therapy for haemophilia A, but new data reported at the ... ASH 2019 congress suggest Pfizer-partnered SB-525 could gain ground.

• AstraZeneca’s Calquence impresses in previously untreated CLL

  The impressive data – presented at ASH 2019 – showed that  Calquence (acalabrutinib) combined with Roche’s  Gazyva(obinutuzumab) significantly improved progression-free survival (PFS) when compared to standard chemo-immunotherapy treatment.